Suppr超能文献

CD47 在肾缺血再灌注损伤发病机制和治疗中的作用。

The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

出版信息

Pediatr Nephrol. 2019 Dec;34(12):2479-2494. doi: 10.1007/s00467-018-4123-z. Epub 2018 Nov 3.

Abstract

Ischemia reperfusion (IR) injury is a process defined by the temporary loss of blood flow and tissue perfusion followed later by restoration of the same. Brief periods of IR can be tolerated with little permanent deficit, but sensitivity varies for different target cells and tissues. Ischemia reperfusion injuries have multiple causes including peripheral vascular disease and surgical interventions that disrupt soft tissue and organ perfusion as occurs in general and reconstructive surgery. Ischemia reperfusion injury is especially prominent in organ transplantation where substantial effort has been focused on protecting the transplanted organ from the consequences of IR. A number of factors mediate IR injury including the production of reactive oxygen species and inflammatory cell infiltration and activation. In the kidney, IR injury is a major cause of acute injury and secondary loss of renal function. Transplant-initiated renal IR is also a stimulus for innate and adaptive immune-mediated transplant dysfunction. The cell surface molecule CD47 negatively modulates cell and tissue responses to stress through limitation of specific homeostatic pathways and initiation of cell death pathways. Herein, a summary of the maladaptive activities of renal CD47 will be considered as well as the possible therapeutic benefit of interfering with CD47 to limit renal IR.

摘要

缺血再灌注 (IR) 损伤是一个由短暂性血流和组织灌注丧失,随后再灌注引起的过程。IR 短暂发作通常可以耐受,很少会造成永久性损伤,但不同的靶细胞和组织的敏感性不同。缺血再灌注损伤有多种原因,包括外周血管疾病和手术干预,这些都会破坏软组织和器官的灌注,就像普通外科和重建外科手术中发生的那样。缺血再灌注损伤在器官移植中尤为突出,因为人们已经投入大量精力来保护移植器官免受 IR 带来的影响。许多因素介导了 IR 损伤,包括活性氧的产生、炎症细胞浸润和激活。在肾脏中,IR 损伤是急性损伤和肾功能继发性丧失的主要原因。移植引起的肾脏 IR 也是导致固有和适应性免疫介导的移植功能障碍的一个刺激因素。细胞表面分子 CD47 通过限制特定的稳态途径和启动细胞死亡途径,对细胞和组织对压力的反应进行负调节。在此,将对肾脏 CD47 的适应不良活性进行综述,并探讨干扰 CD47 以限制肾脏 IR 的可能治疗益处。

相似文献

1
The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.
Pediatr Nephrol. 2019 Dec;34(12):2479-2494. doi: 10.1007/s00467-018-4123-z. Epub 2018 Nov 3.
3
Deficiency in SIRP-α cytoplasmic recruitment confers protection from acute kidney injury.
FASEB J. 2019 Oct;33(10):11528-11540. doi: 10.1096/fj.201900583R. Epub 2019 Aug 1.
4
CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion.
Kidney Int. 2016 Aug;90(2):334-347. doi: 10.1016/j.kint.2016.03.034. Epub 2016 Jun 1.
5
Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury.
J Am Soc Nephrol. 2012 Sep;23(9):1538-50. doi: 10.1681/ASN.2012020137. Epub 2012 Aug 2.
6
Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management.
Am J Physiol Renal Physiol. 2012 Oct 15;303(8):F1117-25. doi: 10.1152/ajprenal.00359.2012. Epub 2012 Aug 8.
7
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling.
Surgery. 2008 Nov;144(5):752-61. doi: 10.1016/j.surg.2008.07.009. Epub 2008 Sep 2.
8
Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases.
Life Sci. 2020 Apr 15;247:117426. doi: 10.1016/j.lfs.2020.117426. Epub 2020 Feb 13.
9
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective.
Plast Reconstr Surg. 2009 Dec;124(6):1880-1889. doi: 10.1097/PRS.0b013e3181bceec3.
10
CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model.
Transplantation. 2014 Aug 27;98(4):394-401. doi: 10.1097/TP.0000000000000252.

引用本文的文献

2
Deciphering the role of CD47 in cancer immunotherapy.
J Adv Res. 2024 Sep;63:129-158. doi: 10.1016/j.jare.2023.10.009. Epub 2023 Oct 28.
4
Asiaticoside ameliorates renal ischemia/reperfusion injury by promoting CD4CD25FOXP3 treg cell differentiation.
Heliyon. 2023 Jun 23;9(7):e17390. doi: 10.1016/j.heliyon.2023.e17390. eCollection 2023 Jul.
5
How to Best Protect Kidneys for Transplantation-Mechanistic Target.
J Clin Med. 2023 Feb 23;12(5):1787. doi: 10.3390/jcm12051787.
6
Emerging phagocytosis checkpoints in cancer immunotherapy.
Signal Transduct Target Ther. 2023 Mar 7;8(1):104. doi: 10.1038/s41392-023-01365-z.
8
Advances in Anti-metabolic Disease Treatments Targeting CD47.
Curr Pharm Des. 2022;28(46):3720-3728. doi: 10.2174/1381612828666221006123144.
10
Microvascular Inflammation of the Renal Allograft: A Reappraisal of the Underlying Mechanisms.
Front Immunol. 2022 Mar 22;13:864730. doi: 10.3389/fimmu.2022.864730. eCollection 2022.

本文引用的文献

1
Cardiac Surgery-Associated Kidney Injury in Children and Renal Oximetry.
Pediatr Crit Care Med. 2018 Sep;19(9):839-845. doi: 10.1097/PCC.0000000000001656.
2
Acute kidney injury after pediatric cardiac surgery.
Pediatr Neonatol. 2019 Feb;60(1):3-11. doi: 10.1016/j.pedneo.2018.03.007. Epub 2018 Mar 30.
3
CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
Cancer Sci. 2018 Aug;109(8):2349-2357. doi: 10.1111/cas.13663. Epub 2018 Jul 4.
8
The matricellular protein TSP1 promotes human and mouse endothelial cell senescence through CD47 and Nox1.
Sci Signal. 2017 Oct 17;10(501):eaaj1784. doi: 10.1126/scisignal.aaj1784.
9
Donor SIRPα polymorphism modulates the innate immune response to allogeneic grafts.
Sci Immunol. 2017 Jun 23;2(12). doi: 10.1126/sciimmunol.aam6202.
10
Pediatric Donor to Adult Recipients in Donation After Cardiac Death Liver Transplantation: A Single-Center Experience.
Transplant Proc. 2017 Jul-Aug;49(6):1383-1387. doi: 10.1016/j.transproceed.2017.01.088.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验